2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.

The protein–protein interaction of p53 and MDM2/X is a promising non genotoxic anticancer target. A rapid and efficient methodology was developed to synthesize the 2,30-bis(10H-indole) heterocyclic scaffold 2 as ester, acid and amide derivatives. Their binding affinity with MDM2 was evaluated using both fluorescence polarization (FP) assay and HSQC experiments, indicating good inhibition and a perfect starting point for further optimizations.

[1]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[2]  F. Boeckler,et al.  Hitting a moving target: targeting transient protein states. , 2013, Structure.

[3]  Alexander Dömling,et al.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. , 2010, Angewandte Chemie.

[4]  J. Hedrick,et al.  Cyclic guanidine organic catalysts: what is magic about triazabicyclodecene? , 2009, The Journal of organic chemistry.

[5]  G. Zambetti,et al.  Mdm‐2: “big brother” of p53 , 1997, Journal of cellular biochemistry.

[6]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[7]  Alexander Dömling,et al.  The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. , 2011, Angewandte Chemie.

[8]  R. R. Yadav,et al.  Meridianin G and its analogs as antimalarial agents , 2013 .

[9]  A. Dömling,et al.  p53-MDM2 and MDMX Antagonists , 2014 .

[10]  Shaomeng Wang,et al.  Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics , 2013 .

[11]  Hsiao-Huei Wu,et al.  MDM2--master regulator of the p53 tumor suppressor protein. , 2000, Gene.

[12]  K. Wüthrich.  NMR of proteins and nucleic acids , 1988 .

[13]  Wei Wang,et al.  Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery , 2010, Cell cycle.

[14]  Paul R. Gerber,et al.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[15]  Su Qiu,et al.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.

[16]  C. Renner,et al.  Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. , 2001, Biochemistry.

[17]  Shaomeng Wang,et al.  Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics , 2012 .

[18]  O. Ottoni,et al.  Acylation of indole under Friedel-Crafts conditions-an improved method to obtain 3-acylindoles regioselectively. , 2001, Organic letters.

[19]  T. Holak,et al.  p53/MDM2 Antagonists: Towards Nongenotoxic Anticancer Treatments , 2013 .

[20]  Takeshi Sakamoto,et al.  A Convenient Synthesis of 1-Alkyl-1-phenylhydrazines from N -Aminophthalimide , 2003 .

[21]  P. Furet,et al.  The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction. , 2012, Bioorganic & Medicinal Chemistry Letters.

[22]  R. Huber,et al.  Application of NMR in structural proteomics: screening for proteins amenable to structural analysis. , 2002, Structure.

[23]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[24]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[25]  P. Furet,et al.  Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. , 2000, Journal of medicinal chemistry.

[26]  Alexander Dömling,et al.  Transient protein states in designing inhibitors of the MDM2-p53 interaction. , 2013, Structure.

[27]  G. Dubin,et al.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx , 2009, Cell cycle.

[28]  T. Owa,et al.  A general method for acylation of indoles at the 3-position with acyl chlorides in the presence of dialkylaluminum chloride. , 2000, Organic letters.

[29]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[30]  L. Weber,et al.  Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present) , 2013, Expert opinion on therapeutic patents.

[31]  C. Klein,et al.  p53--a natural cancer killer: structural insights and therapeutic concepts. , 2006, Angewandte Chemie.

[32]  Weiqi Wang,et al.  Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists. , 2009, Journal of combinatorial chemistry.

[33]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[34]  Martin Stahl,et al.  Rationalizing Tight Ligand Binding through Cooperative Interaction Networks , 2011, J. Chem. Inf. Model..

[35]  A. Ciechanover,et al.  HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53 , 2003, Proceedings of the National Academy of Sciences of the United States of America.